O	0	10	Randomized
O	11	21	controlled
O	22	27	trial
O	28	30	on
O	31	44	effectiveness
O	45	47	of
B-intervention	48	63	ultrasonography
I-intervention	64	73	screening
O	74	77	for
O	78	84	breast
O	85	91	cancer
O	92	94	in
O	95	100	women
B-age	101	105	aged
I-age	106	108	40
I-age	108	109	-
I-age	109	111	49
O	112	113	(
O	113	114	J
O	114	115	-
O	115	120	START
O	120	121	)
O	121	122	:
O	123	131	research
O	132	138	design
O	138	139	.

O	140	142	In
O	143	149	cancer
O	150	159	screening
O	159	160	,
O	161	163	it
O	164	166	is
O	167	176	essential
O	177	179	to
O	180	189	undertake
O	190	199	effective
O	200	209	screening
O	210	214	with
O	215	226	appropriate
O	227	238	methodology
O	238	239	,
O	240	245	which
O	246	252	should
O	253	255	be
O	256	265	supported
O	266	268	by
O	269	277	evidence
O	278	280	of
O	281	282	a
O	283	290	reduced
O	291	300	mortality
O	301	305	rate
O	305	306	.

O	307	309	At
O	310	317	present
O	317	318	,
O	319	330	mammography
O	331	333	is
O	334	337	the
O	338	342	only
O	343	349	method
O	350	353	for
O	354	360	breast
O	361	367	cancer
O	368	377	screening
O	378	382	with
O	383	387	such
O	388	396	evidence
O	396	397	.

O	398	405	However
O	405	406	,
O	407	418	mammography
O	419	423	does
O	424	427	not
O	428	435	achieve
O	436	446	sufficient
O	447	455	accuracy
O	456	458	in
O	459	466	breasts
O	467	471	with
O	472	476	high
O	477	484	density
O	485	487	at
O	488	492	ages
O	493	498	below
O	499	501	50
O	501	502	.

O	503	511	Although
O	512	527	ultrasonography
O	528	536	achieves
O	537	543	better
O	544	552	accuracy
O	553	555	in
O	556	562	Breast
O	563	569	Cancer
O	570	579	detection
O	580	584	even
O	585	587	in
O	588	593	dense
O	594	601	breasts
O	601	602	,
O	603	606	the
O	607	620	effectiveness
O	621	624	has
O	625	628	not
O	629	633	been
O	634	642	verified
O	642	643	.

O	644	646	We
O	647	651	have
O	652	659	planned
O	660	661	a
O	662	672	randomized
O	673	683	controlled
O	684	689	trial
O	690	692	to
O	693	699	assess
O	700	703	the
O	704	717	effectiveness
O	718	720	of
O	721	736	ultrasonography
O	737	739	in
O	740	745	women
O	746	750	aged
O	751	753	40
O	753	754	-
O	754	756	49
O	756	757	,
O	758	762	with
O	763	764	a
O	765	771	design
O	772	774	to
O	775	780	study
B-intervention-participants	781	783	50
I-intervention-participants	783	784	,
I-intervention-participants	784	787	000
O	788	793	women
O	794	798	with
O	799	810	mammography
O	811	814	and
O	815	830	ultrasonography
O	831	832	(
O	832	844	intervention
O	845	850	group
O	850	851	)
O	851	852	,
O	853	856	and
B-control-participants	857	859	50
I-control-participants	859	860	,
I-control-participants	860	863	000
O	864	872	controls
O	873	877	with
B-control	878	889	mammography
I-control	890	894	only
I-control	895	896	(
I-control	896	903	control
I-control	904	909	group
I-control	909	910	)
O	910	911	.

O	912	915	The
O	916	928	participants
O	929	932	are
O	933	942	scheduled
O	943	945	to
O	946	950	take
O	951	957	second
O	958	963	round
O	964	973	screening
O	974	978	with
O	979	982	the
O	983	987	same
O	988	996	modality
O	997	998	2
O	999	1004	years
O	1005	1007	on
O	1007	1008	.

O	1009	1012	The
O	1013	1020	primary
O	1021	1030	endpoints
O	1031	1034	are
B-outcome-Measure	1035	1046	sensitivity
I-outcome-Measure	1047	1050	and
I-outcome-Measure	1051	1062	specificity
O	1062	1063	,
O	1064	1067	and
O	1068	1071	the
O	1072	1081	secondary
O	1082	1090	endpoint
O	1091	1093	is
O	1094	1097	the
B-outcome-Measure	1098	1102	rate
I-outcome-Measure	1103	1105	of
I-outcome-Measure	1106	1114	advanced
I-outcome-Measure	1115	1121	breast
I-outcome-Measure	1122	1129	cancers
O	1129	1130	.
